1-4 of 4
Douglas B. Flieder
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

SAR-096: Phase II Clinical Trial of Ribociclib in Combination with Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)

Available to Purchase
Sujana Movva, Sahar Matloob, Elizabeth A. Handorf, Edwin Choy, Priscilla Merriam, Douglas B. Flieder, Kathy Q. Cai, Yan Zhou, Eric D. Tetzlaff, Cheyenne Pagan, Emma Barker, Rosanna Veggeberg, Delia Zumpano, Lori Rink, Margaret von Mehren, Suzanne George
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (2): 315–322.
https://doi.org/10.1158/1078-0432.CCR-23-2469
Published: 17 January 2024
View articletitled, SAR-096: Phase II Clinical Trial of Ribociclib in Combination with Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)
Open the PDF for SAR-096: Phase II Clinical Trial of Ribociclib in Combination with Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS) in another window
Includes: Supplementary data
Journal Articles

Linsitinib (OSI-906) for the Treatment of Adult and Pediatric Wild-Type Gastrointestinal Stromal Tumors, a SARC Phase II Study

Available to Purchase
Margaret von Mehren, Suzanne George, Michael C. Heinrich, Scott M. Schuetze, Jeffrey T. Yap, Jain Q. Yu, Amanda Abbott, Samuel Litwin, John Crowley, Martin Belinsky, Katherine A. Janeway, Jason L. Hornick, Douglas B. Flieder, Rashmi Chugh, Lori Rink, Annick D. Van den Abbeele
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (8): 1837–1845.
https://doi.org/10.1158/1078-0432.CCR-19-1069
Published: 15 April 2020
View articletitled, Linsitinib (OSI-906) for the Treatment of Adult and Pediatric Wild-Type Gastrointestinal Stromal Tumors, a SARC Phase II Study
Open the PDF for Linsitinib (OSI-906) for the Treatment of Adult and Pediatric Wild-Type Gastrointestinal Stromal Tumors, a SARC Phase II Study in another window
Journal Articles

Quantification of Excision Repair Cross-Complementing Group 1 and Survival in p16-Negative Squamous Cell Head and Neck Cancers

Free
Ranee Mehra, Fang Zhu, Dong-Hua Yang, Kathy Q. Cai, JoEllen Weaver, Mahendra K. Singh, Anna S. Nikonova, Erica A. Golemis, Douglas B. Flieder, Harry S. Cooper, Miriam Lango, John A. Ridge, Barbara Burtness
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (23): 6633–6643.
https://doi.org/10.1158/1078-0432.CCR-13-0152
Published: 01 December 2013
View articletitled, Quantification of Excision Repair Cross-Complementing Group 1 and Survival in p16-Negative Squamous Cell Head and Neck Cancers
Open the PDF for Quantification of Excision Repair Cross-Complementing Group 1 and Survival in p16-Negative Squamous Cell Head and Neck Cancers in another window
Includes: Supplementary data
Journal Articles

Prognostic Implications of Molecular and Immunohistochemical Profiles of the Rb and p53 Cell Cycle Regulatory Pathways in Primary Non–Small Cell Lung Carcinoma

Free
Louise Burke, Douglas B. Flieder, Donald G. Guinee, Elizabeth Brambilla, Andrew N. Freedman, William P. Bennett, Raymond T. Jones, Andrew Borkowski, Neil A. Caporaso, Marian Fleming, Victor Trastek, Peter Pairolero, Henry Tazelaar, David Midthun, James R. Jett, Lance A. Liotta, William D. Travis, Curtis C. Harris
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (1): 232–241.
https://doi.org/10.1158/1078-0432.232.11.1
Published: 21 January 2005
View articletitled, Prognostic Implications of Molecular and Immunohistochemical Profiles of the Rb and p53 Cell Cycle Regulatory Pathways in Primary Non–Small Cell Lung Carcinoma
Open the PDF for Prognostic Implications of Molecular and Immunohistochemical Profiles of the Rb and p53 Cell Cycle Regulatory Pathways in Primary Non–Small Cell Lung Carcinoma in another window
Includes: Supplementary data